Related Experiment Videos
Synergic activity of imipenem/cilastatin combined with cefotiam against methicillin-resistant Staphylococcus aureus
Abstract:
The synergic activity of imipenem/cilastatin combined with cefotiam was studied in a mouse bacteraemia model. Combinations of imipenem plus cefotiam in ratios from 1:5 to 1:160 were more effective than either imipenem alone or cefotiam alone (P < 0.05). Synergy was observed against both beta-lactamase producing and beta-lactamase non-producing MRSA. Staggered combinations of imipenem with cefotiam (each drug was administered at a different time) were studied in an in-vitro pharmacokinetic system to clarify relationships between killing kinetics and pharmacodynamics of the combinations. In the in-vitro system, cefotiam (1 g over 30 min) administered 2 h after imipenem administration (250 mg over 30 min) reduced viable cell counts to an undetectable level and maintained this for 4 h, while the simultaneous administration of imipenem and cefotiam maintained an undetectable cell count for only 2 h. Furthermore, imipenem administered after cefotiam showed no synergy. These results indicate that the timing of dosing of each antibiotic influences synergy, and administration of cefotiam 2 h after imipenem is more effective than the other regimens.
Insights
The combination of imipenem/cilastatin and cefotiam shows synergistic activity against MRSA infections. Optimal effectiveness is achieved when cefotiam is administered 2 hours after imipenem/cilastatin.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat due to antibiotic resistance.
- Combination antibiotic therapy is explored to enhance efficacy against resistant pathogens.
Purpose of the Study:
- To investigate the synergistic activity of imipenem/cilastatin combined with cefotiam against MRSA.
- To determine the optimal dosing strategy for this antibiotic combination.
Main Methods:
- A mouse bacteremia model was used to evaluate in vivo efficacy.
- An in vitro pharmacokinetic system assessed killing kinetics and pharmacodynamics.
- Different administration timings and ratios of imipenem/cilastatin and cefotiam were tested.
Main Results:
- The combination of imipenem/cilastatin and cefotiam demonstrated synergistic activity against both beta-lactamase producing and non-producing MRSA.
- Administering cefotiam 2 hours after imipenem/cilastatin resulted in sustained bacterial eradication in vitro.
- Simultaneous or reversed administration (imipenem after cefotiam) showed reduced or no synergistic effect.
Conclusions:
- The timing of antibiotic administration is critical for achieving synergy with imipenem/cilastatin and cefotiam.
- A staggered dosing regimen, with cefotiam following imipenem/cilastatin by 2 hours, is superior for MRSA treatment.